8-K: CalciMedica Reports Q3 2025 Results, Advances Clinical Trials

CalciMedica announced its third quarter 2025 financial results, highlighting ongoing enrollment in its Phase 2 KOURAGE trial and positive FDA discussions for a pivotal AP trial.

Summary

• Net loss for the third quarter ended September 30, 2025, was $7.8 million, or $0.52 per basic and diluted share, compared to a net loss of $5.6 million, or $0.50 per basic and diluted share, for the same period in 2024.
• Cash, cash equivalents, and short-term investments totaled $14.1 million as of September 30, 2025.
• The company expects its cash position to be sufficient to fund current operating plans into the second half of 2026.
• Enrollment is ongoing in the Phase 2 KOURAGE trial evaluating Auxora in patients with acute kidney injury (AKI) with respiratory failure, with data expected in the first half of 2026.
• Positive discussions have been held with the FDA regarding the design of a pivotal trial for Auxora in acute pancreatitis (AP), with the final trial design expected in the first half of 2026.
• A collaboration with Telperian was announced in October 2025 to leverage AI-driven analytics to optimize the design of the pivotal AP trial.
• Preclinical data for Auxora, presented at ASN Kidney Week 2025, showed it improved kidney function, reduced Th17 cells in kidney and lung, increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of AKI.
• Preclinical data for CM5480, a proprietary CRAC channel inhibitor, was published in JCI Insight, supporting its potential as a therapy for pulmonary arterial hypertension (PAH) and demonstrating significant reduction in right ventricular dysfunction (RVD).
• Research and development expenses increased to $3.9 million for Q3 2025 from $3.6 million for Q3 2024, primarily due to increased clinical trial and preclinical activities.
• General and administrative expenses decreased to $1.8 million for Q3 2025 from $2.2 million for Q3 2024, mainly due to a decrease in professional services and consultants.
• Other expenses were $2.2 million for Q3 2025, compared to other income of $0.1 million for Q3 2024, primarily due to a non-cash increase in fair value adjustments to financial instruments.

Sentiment

Score: 6

Explanation: While the company reported an increased net loss and decreased cash position, significant clinical and preclinical progress, positive FDA discussions, and a collaboration leveraging AI for trial design provide a positive outlook for its pipeline, balancing the financial negatives. The cash runway into 2H 2026 provides some stability.

Positives

• Enrollment is ongoing in the Phase 2 KOURAGE trial for Auxora in AKI with respiratory failure, with data anticipated in 1H 2026.
• Positive discussions have been held with the FDA regarding the design of a pivotal trial for Auxora in AP, with final design expected in 1H 2026.
• A collaboration with Telperian was announced to leverage AI insights for optimizing the AP pivotal trial design.
• Preclinical data for Auxora in AKI rat models demonstrated significant improvements, including reduced Th17 cells, increased GFR, and decreased renal injury.
• Preclinical data for CM5480, a CRAC channel inhibitor, published in JCI Insight, supports its potential for PAH and showed improvement in RVD as monotherapy and in combination with existing therapies.
• The company's cash position is expected to fund operations into the second half of 2026, providing runway for ongoing clinical programs.
• General and administrative expenses decreased by $0.4 million in Q3 2025 compared to Q3 2024.

Negatives

• Net loss increased to $7.8 million in Q3 2025 from $5.6 million in Q3 2024.
• Net loss per basic and diluted share increased to $0.52 in Q3 2025 from $0.50 in Q3 2024.
• Other expenses significantly increased by $2.3 million, primarily due to non-cash fair value adjustments to financial instruments.
• Cash, cash equivalents, and short-term investments decreased to $14.1 million as of September 30, 2025, from $19.665 million in total current assets as of December 31, 2024.

Risks

• The impact of fluctuations in global financial markets on CalciMedica's business and the actions it may take in response thereto.
• CalciMedica's ability to execute its plans and strategies.
• The ability to obtain and maintain regulatory approval for Auxora.
• Results from clinical trials or preclinical studies may not be indicative of results that may be observed in the future.
• Potential safety and other complications from Auxora.
• The scope, progress, and expansion of developing and commercializing Auxora.
• The size and growth of the market therefor and the rate and degree of market acceptance thereof.
• Economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally.
• CalciMedica's ability to protect its intellectual property position.
• The impact of government laws and regulations.
• CalciMedica's financial position and need for additional capital.

Future Outlook

CalciMedica expects to release data from its Phase 2 KOURAGE trial in AKI with respiratory failure in the first half of 2026 and finalize the design of its pivotal trial in AP in the first half of 2026. The collaboration with Telperian is anticipated to optimize the AP pivotal trial design. The company's cash position is projected to fund operations into the second half of 2026.

Management Comments

• "Enrollment continues in our Phase 2 KOURAGE trial evaluating Auxora in patients with AKI with respiratory failure, and we look forward to sharing data in the first half of 2026."
• "As we approach this milestone, we are encouraged by AKI animal model data recently shared at ASN and results in PAH animal models published in JCI Insight, both of which provide further mechanistic rationale for CRAC channel inhibition as a promising approach for treating AKI."
• "Additionally, discussions with the FDA have been positive regarding our program in AP. We expect our recently announced collaboration with Telperian and its AI-driven analytics platform will enable us to leverage insights from completed Auxora trials to optimize the design of our pivotal trial in AP, which we expect to finalize in the first half of 2026."

Industry Context

CalciMedica is developing novel CRAC channel inhibition therapies, positioning itself in the competitive biopharmaceutical landscape targeting inflammatory and immunologic diseases with high unmet medical needs, such as severe AKI and AP. The positive preclinical data for Auxora in AKI and CM5480 in PAH, coupled with ongoing clinical trials, demonstrate the company's commitment to advancing its pipeline. The strategic collaboration with Telperian to integrate AI into trial design reflects a broader industry trend towards leveraging advanced analytics to enhance the efficiency and success rates of drug development programs.

Comparison to Industry Standards

• Auxora has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and has been well-tolerated in over 350 critically ill patients, indicating a robust safety profile for a clinical-stage asset.
• The anticipated pivotal trial in AP is expected to be the first pivotal trial in the U.S. for a therapeutic in acute pancreatitis, potentially offering a first-in-class treatment for a condition with no currently approved therapies.
• The collaboration with Telperian and its AI-driven analytics platform for trial design optimization aligns with leading industry practices aimed at improving clinical development efficiency and outcomes.
• Preclinical data for CM5480 showing restoration or improvement of multiple disease-affected pathways and functions in PAH animal models, including heart contraction and cardiac output, suggests a broad therapeutic potential that could differentiate it from existing PAH therapies.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline advancement, but short-term dilution risk due to increased net loss and future capital needs.
• Patients: Potential for new therapeutic options for severe AKI with respiratory failure and acute pancreatitis, conditions with high unmet medical needs.
• Employees: Continued employment and focus on clinical development.
• Regulatory Authorities (FDA): Ongoing engagement and positive discussions regarding pivotal trial design.
• Collaborators (Telperian, Indiana University School of Medicine): Continued partnership in advancing research and trial optimization.

Next Steps

• Continue enrollment in Phase 2 KOURAGE trial for AKI with respiratory failure.
• Release data from Phase 2 KOURAGE trial in 1H 2026.
• Finalize pivotal trial design for AP in 1H 2026.
• Leverage Telperian's AI platform to optimize AP pivotal trial design.
• File Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Key Dates

Recommendation

The company shows promising clinical progress with Auxora in AKI and AP, including positive FDA discussions and a strategic AI collaboration. Preclinical data for CM5480 also adds to the long-term pipeline potential. However, the increased net loss and declining cash position, despite a runway into 2H 2026, indicate ongoing financial challenges and a likely need for future capital raises, which could lead to dilution. The stock is a 'hold' for investors monitoring the clinical milestones and regulatory progress, but cautious due to the financial burn rate and the inherent risks of clinical-stage biopharmaceutical development.

Keywords

CalciMedica, CALC, biopharmaceutical, clinical-stage, CRAC channel inhibition, Auxora, acute kidney injury, AKI, respiratory failure, KOURAGE trial, acute pancreatitis, AP, pivotal trial, FDA, Telperian, AI platform, CM5480, pulmonary arterial hypertension, PAH, right ventricular dysfunction, RVD, Q3 2025 financial results, biotech, drug development, inflammatory diseases, immunologic diseases